Abeona Therapeutics
Commercial-stage cell and gene therapy company. Its ZEVASKYN (prademagene zamikeracel) autologous cell sheet was approved by the FDA in April 2025 for recessive dystrophic epidermolysis bullosa, and FAYUVI (ABO-102) became the company's second approved gene therapy in 2026 for mucopolysaccharidosis type IIIA. Abeona added APT-1011 (ABO-801), a Phase 3-ready orally disintegrating fluticasone formulation for eosinophilic esophagitis, in November 2026 and is advancing its SIR-T synthetic immune receptor platform, led by PSMA-targeted ABO-701 for advanced prostate cancer.
Company Info
Sector:Cell & Gene Therapy
Headquarters:Cleveland, OH, USA
Founded:2015
Website:www.abeonatherapeutics.com/
Clinical Development Pipeline
ZEVASKYN (prademagene zamikeracel)
Target: COL7A1 gene-corrected autologous cell sheetFAYUVI (ABO-102)
Target: AAV9-mediated SGSH gene therapyAPT-1011 (ABO-801)
Target: Fluticasone propionate orally disintegrating tabletRecent News
No recent news updates available for this company.
Leadership Team
Vishwas Seshadri
President & Chief Executive Officer
Joseph Vazzano
Chief Financial Officer